site:www.biopharmadive.com - 搜索图片

1200 x 675 ·
www.biopharmadive.com
Intellia starts late-stage test of CRISPR therapy for rare swelling disease | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Merck claims late-stage study success for RSV antibody | BioPharma Dive
1200 x 675 ·
www.biopharmadive.com
New data underline cancer risk of Bluebird therapy for brain disease | BioPharma Dive

1200 x 675 ·
www.biopharmadive.com
Purespring raises $105M to advance gene therapy for kidney disease | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit | BioPharma Dive
1200 x 675 ·
www.biopharmadive.com
Sanofi’s rare disease drug finds yet another home | BioPharma Dive

1200 x 675 ·
www.biopharmadive.com
Amgen shares soar as executives outline obesity drug push | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
AstraZeneca stays in GLP-1 drug race with new deal | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Lilly counts on manufacturing scale-up to unstick obesity drug supply | BioPharma Dive

1200 x 675 ·
www.biopharmadive.com
Lilly counts on manufacturing scale-up to unstick obesity drug supply | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Lilly counts on manufacturing scale-up to unstick obesity drug supply | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Investors put $400M into biotech licensing obesity drugs from China | BioPharma Dive

1200 x 675 · jpeg
www.biopharmadive.com
Madrigal wins FDA approval of first drug for MASH | BioPharma Dive
1200 x 675 ·
www.biopharmadive.com
First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Women with a common hormonal disorder have few good treatment options. Could GLP-1 drugs help ...

1200 x 675 · jpeg
www.biopharmadive.com
Lilly counts on manufacturing scale-up to unstick obesity drug supply | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Lilly counts on manufacturing scale-up to unstick obesity drug supply | BioPharma Dive
1200 x 675 · jpeg
www.biopharmadive.com
Bluebird gene therapy, now approved for sickle cell, shows durable benefit in study update ...

1200 x 675 ·
www.biopharmadive.com
Upstream prices $255M IPO in bid to challenge Amgen, AstraZeneca asthma drug | BioPharma Dive

某些结果已被隐藏，因为你可能无法访问这些结果。显示无法访问的结果